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USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION 
Required software to e-Annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 11
or above). (Note that this document uses screenshots from Adobe Reader 'C.)
The latest version of Acrobat Reader can be downloaded for free at: http://get.adobe.com/reader/
Once you have Acrobat Reader open on your computer, click on the Comment tab
right-hand panel or under the 7ools menu).
7his will open up a ribbon panel at the top oI the document. Using a tool will place 
a comment in the right-hand panel. 7he tools \ou will use Ior annotating \our prooI 
are shown below
1. Replace (Ins) Tool – for replacing text.
Strikes a line through text and opens up a text 
box where replacement text can be entered.
How to use it:
 Highlight a word or sentence.
 Click on  .
 Type the replacement text into the blue box that
appears.
2. Strikethrough (Del) Tool – for deleting text.
Strikes a red line through text that is to be 
deleted.
How to use it:
 Highlight a word or sentence.
 Click on  ..  
3. Commenting Tool – for highlighting a section
to be changed to bold or italic or for general
comments.
How to use it:


Click on  .
 Type any instructions regarding the text to be
altered into the box that appears.
4. Insert Tool – for inserting missing text
at specific points in the text.
Use these 2 tools to highlight the text 
where a comment is then made.
How to use it:
 Click on  .
 Click at the point in the proof where the comment
should be inserted.
 Type the comment into the box that
appears.
Marks an insertion point in the text and
opens up a text box where comments 
can be entered.
&lick and drag over the te[t you need to 
highlight for the comment you will add.
 7he te[t will be struck out  in red.
 &lick on         .  
 &lick close to the text you just highlighted.
USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION 
For further information on how to annotate proofs, click on the Help menu to reveal a list of further options: 
5. Attach File Tool – for inserting large amounts of
text or replacement figures. 
Inserts an icon linking to the attached file in the 
appropriate place in the text.
How to use it:
 Click on  .
 Click on the proof to where you’d like the attached
file to be linked.
 Select the file to be attached from your computer
or network.
 Select the colour and type of icon that will appear
in the proof. Click OK.
The attachment appears in the right-hand panel.
6. Add stamp Tool – for approving a proof if no
corrections are required. 
Inserts a selected stamp onto an appropriate 
place in the proof. 
How to use it:
 Click on  .
 Select the stamp you want to use. (The Approved
stamp is usually available directly in the menu that
appears. Others are shown under Dynamic, Sign
Here, Standard Business).
 Fill in any details and then click on the proof
where you’d like the stamp to appear. (Where a
proof is to be approved as it is, this would
normally be on the first page).
7. Drawing Markups Tools – for drawing shapes, lines, and freeform
annotations on proofs and commenting on these marks. 
Allows shapes, lines, and freeform annotations to be drawn on proofs and
for comments to be made on these marks.
How to use it:
 Click on one of the shapes in the Drawing
Markups section.
 Click on the proof at the relevant point and
draw the selected shape with the cursor.
 To add a comment to the drawn shape,
right-click on shape and select Open
Pop-up Note.
 Type any text in the red box that
appears.
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Cryopreservation of Canine Cardiosphere-
Derived Cells: Implications for Clinical
Application
Luke C. DuttonAQ11 ,1* Sophie A.V. Church,1 Hannah Hodgkiss-Geere,2 Brian Catchpole,3
Anthony Huggins,3 Jayesh Dudhia,1† David J. Connolly1†
 Abstract
The clinical application of cardiosphere-derived cells (CDCs) to treat cardiac disease
has gained increasing interest over the past decade. Recent clinical trials confirm their
regenerative capabilities, although much remains to be elucidated about their basic
biology. To develop this new treatment modality, in a cost effective and standardized
workflow, necessitates the creation of cryopreserved cell lines to facilitate access for car-
diac patients requiring urgent therapy. Cryopreservation may however lead to altera-
tions in cell behavior and potency. The aim of this study was to investigate the effect of
cryopreservation on canine CDCs. CDCs and mesenchymal stem cells (MSCs) isolated
from five dogs were characterized. CDCs demonstrated a population doubling time
that was unchanged by cryopreservation (fresh vs. cryopreserved; 57.136 5.27 h vs.
48.946 9.55 h, P5 0.71). This was slower than for MSCs (30.46 h, P< 0.05). The abil-
ity to form clones, self-renew, and commit to multiple lineages was unaffected by cryo-
preservation. Cryopreserved CDCs formed larger cardiospheres compared to fresh cells
(P< 0.0001). Fresh CDCs showed a high proportion of CD1051 (89.0%6 4.98) and
CD441 (99.68%6 0.13) cells with varying proportions of CD901 (23.36%6 9.78),
CD341 (7.18%6 4.03) and c-Kit1 (13.17%6 8.67) cells. CD451 (0.015%6 0.005)
and CD291 (2.92%6 2.46) populations were negligible. Increasing passage number of
fresh CDCs correlated with an increase in the proportion of CD341 and a decrease in
CD901 cells (P5 0.003 and 0.03, respectively). Cryopreserved CDCs displayed
increased CD341 (P< 0.001) and decreased CD901 cells (P5 0.042) when compared
to fresh cells. Overall, our study shows that cryopreservation of canine CDCs is feasible
without altering their stem characteristics, thereby facilitating their utilization for clini-
cal trials. VC 2017 International Society for Advancement of Cytometry
 Key terms
cardiosphere-derived cells; canine; cryopreservation; differentiation; stem cells
NON -ischemic dilated cardiomyopathy (DCM) is the second most common cardiac
disease of dogs, accounting for 10% of canine cardiac diagnoses (1). DCM is a het-
erogeneous disease of the canine myocardium that demonstrates breed specific char-
acteristics at pathological and clinical levels (2). An underlying genetic basis has been
proposed in a number of breeds, including the Doberman and Boxer, where the dis-
ease has been studied in detail and shown to be both common and severe with a
cumulative prevalence in European Dobermans >8 years of age of 44% (2–7). Two
distinct histopathological variations of canine DCM have been described; attenuated
wavy fiber type and fibro-fatty infiltration type (7). Fibro-fatty infiltration is consid-
ered analogous to arrhythmogenic right ventricular cardiomyopathy (ARVC) in
humans because of the comparable pathological changes and clinical presentation
between the two species (8–12). Although the pathophysiologic mechanism underly-
ing ARVC remains unclear, it is thought to include molecular pathways involved in
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the formation of mechanical and electrical coupling, apopto-
sis, and migration and differentiation of epicardial-derived
cells (13). The electrical uncoupling together with fibro-fatty
replacement of the myocardium are considered primary sub-
strates for arrhythmia and sudden cardiac death is a frequent
consequence (10). Dogs that survive develop progressive ven-
tricular dilation and systolic dysfunction leading to congestive
heart failure (12,14). Similar to humans, treatment options
are limited and directed toward controlling clinical signs but
do not promote myocardial repair or ultimately reduce disease
progression.
Since the discovery that the adult heart had regenerative
ability there has been increasing interest in the therapeutic use
of adult cardiac stem cells (15,16). Multiple populations of
cardiac progenitor cells have been isolated, such as side popu-
lation cells, stem-cell antigen positive cells (Sca-11), c-Kit1
(also known as CD117) cells, Islet-11 cells, cardiospheres, and
cardiosphere-derived cells (CDCs) (17–23). CDCs in particu-
lar have drawn much attention since there is mounting evi-
dence they contribute to myocardial repair (22,24–27). Phase
1 clinical trials in humans have shown improved cardiac func-
tion using autologous CDCs (28,29). Allogeneic CDC therapy
was shown to be safe, with marginal improvement in cardiac
function, in a small clinical trial in Dobermans with DCM;
however, there was no increase in survival time (30).
CDCs represent a heterogeneous cardiac stem cell popu-
lation with the ability to form clones, self-renew and commit
to multiple lineages including smooth muscle, myocardium,
and endothelium (25,31,32). CDCs are isolated from an inter-
mediate cell population of cardiospheres which have been
generated using various methods, including plating of cardiac
outgrowth cells on poly-D-lysine coated wells (21,33), the use
of forced aggregation on low attachment surfaces (25,30),
aggregation plates and the hanging drop method (32). Cardio-
spheres are then cultured on plastic to form a monolayer of
CDCs, which can be readily passaged and expanded to clini-
cally useful cell numbers (28).
The development of a cost effective and efficient clinical
treatment would necessitate the creation of cell banks for allo-
geneic applications, where cardiac stem cells from donor dogs
could be cultured, characterized, assessed for endotoxins,
purity, and subsequently cryopreserved. The aim of this work
was to investigate the immunophenotype and basic cellular
characteristics of canine CDCs prior to and following
cryopreservation.
MATERIALS AND METHODS
Tissue Preparation
Canine tissue was obtained immediately post-mortem
from five cadavers with owners’ informed consent following
approval by the Royal Veterinary College Ethics and Welfare
Committee (Approval number: URN 2013 1246). Donors
were aged 0.5, 4, 5, 5, and 6 years. Full thickness atrial tissue
was aseptically removed and placed in chilled cardiac explant
medium (CEM) consisting of Iscove’s Modified Dulbecco’s
Medium (IMDM), 10% fetal bovine serum (FBS), 1% L-
glutamine, 1% penicillin-streptomycin (P/S) (all from
Thermo Fisher Scientific), and 0.1 mmol/l 2-mercaptoethanol
(2-ME) (Sigma-Aldrich). Subcutaneous adipose tissue was
harvested from the popliteal region and placed in mesenchy-
mal stem cell media (MSCM) consisting of high glucose
(4.5 g/l) Dulbecco’s Modified Eagle’s Medium (DMEM)
(Thermo Fisher Scientific) supplemented with 10% FBS and
1% P/S.
Preparation of Cardiosphere-Derived Cells
Atrial tissue was minced into <1 mm3 explants and
washed with Dulbecco’s Phosphate-Buffered Saline (DPBS)
(Thermo Fisher Scientific). The explants were digested in
0.2% trypsin and 0.1% collagenase IV (both from Thermo
Fisher Scientific) three times for 5 min each at 378C. After the
final digestion, explants were placed in 5 ml of CEM for 5 min
and then transferred onto fibronectin (Thermo Fisher Scien-
tific) coated 25 cm2 tissue culture flasks (Greiner Bio One)
with 2–3 explants per flask. These were allowed to adhere for
30–60 min, after which 5–7 ml of CEM media was added and
incubated in standard tissue culture conditions (378C and 5%
CO2 in humidified air) to allow a stromal-like cell layer to
emerge as an outgrowth from the explants over a period of 3–
7 days, during which time phase-bright cells appeared above
the cell monolayer (21,31,33). Cells were detached with Try-
pLE Express (Thermo Fisher Scientific) and plated at a density
of 1 3 105/cm2 on Ultra-Low Attachment flasks (ULA)
(Corning) in CEM containing 10% FBS. Once cardiospheres
had formed over 5–7 days, they were collected and seeded
onto fibronectin coated flasks to yield cardiosphere-derived
cells (CDCs) in CEM with 20% FBS. Cells were passaged at
60–80% confluence by washing twice with DPBS and incubat-
ing with 0.25% trypsin (Thermo Fisher Scientific) for 5 min
in tissue culture conditions. Trypsin was inactivated by adding
an equal volume of CEM and cells centrifuged at 400 g for 7
min. CDCs were cryopreserved in CellBanker 2 medium
(AMS Biotechnology Ltd.) at a density of 1–2 3 106/ml and
temperature decrease of 218C/min in a freezing container
(Mr Frosty, Thermo Fisher Scientific) to 2808C. CDCs were
transferred to liquid nitrogen storage after 24 h.
Preparation of Mesenchymal Stem Cells
Canine adipose-derived mesenchymal stem cells (MSCs)
were isolated as previously described (34–36). This cell type
was used for comparison since they can be readily obtained,
cultured, and is the most comprehensively characterized
canine adult stem cell. Briefly, tissue samples were washed
twice with 5 ml of DPBS, finely minced with scissors and then
incubated with 0.2% collagenase IV at 378C with mild agita-
tion (40 rpm) for 45 min. The resulting suspension was fil-
tered through a 70 mm nylon cell strainer (Corning) and
centrifuged at 1,000 g for 10 min. The supernatant was dis-
carded and the cell pellet re-suspended in 1 ml of MSCM.
Cells were counted by Trypan blue (Sigma-Aldrich) dye exclu-
sion and seeded onto 25 cm2 tissue culture flasks at a density
of 3–5 3 104 cells/cm2. These were incubated in tissue culture
conditions. After 24 h unattached cells were removed with
two DPBS washes. Cells were passaged and cryopreserved as
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described for CDCs. Both fresh and cryopreserved MSCs were
used for analysis, since cryopreservation has been shown to
not alter their stem characteristics (37).
Cellular assays were performed on at least three donor
(biological) samples with three technical replicates for each
donor sample.
Antibody Staining for Flow Cytometry
Cryopreserved cells were rapidly thawed at 378C, re-
suspended in appropriate growth media, washed once by
centrifugation at 400 g for 7 min and cultured in the same
conditions as fresh cells for 3–5 days prior to antibody stain-
ing. Fresh cells were used directly from tissue culture vessels.
Cells were detached by washing twice with DPBS and incubat-
ing at 378C with Accutase (Thermo Fisher Scientific).
Recovered cells were pelleted by centrifugation (400 g for 5
min at 208C), pellets were washed with chilled (48C) FACS
buffer (FACSFlow; BD Biosciences), re-suspended at a con-
centration of 3 3 106/ml in FACS buffer and 100 ml aliquots
transferred into FACS tubes (Thermo Fisher Scientific).
Monoclonal antibodies or isotope-matched controls were
added to each tube and incubated for 30 min at 48C protected
from light. Cells were pelleted by centrifugation at 400 g for 5
min at 48C, washed by re-suspension in FACS buffer and sus-
pended in 1 ml of FACS buffer for acquisition. The antibodies
used were anti-canine CD90 (eBioscience, clone YKIX337.217,
1:20 dilution), anti-mouse CD105 (BD Biosciences, clone
MJ7/18, 1:10), anti-human CD44 (Biolegend, clone IM7,
1:20), anti-human CD29 (BD Bioscience, clone MAR4, 1:20),
anti-canine CD34 (R&D Systems, clone IH6, 1:10), anti-
canine CD45 (Bio-rad, clone YKIX716.13, 1:10), and anti-
human CD117 (BD Bioscience, clone YB5.B8, 1:10). Isotype
controls were mouse IgG1 for CD34, CD29, and CD117 (BD
Bioscience, clone MOPC-21, 1:10), rat IgG2b for CD90,
CD45, and CD44 (eBioscience, clone eB149/10H5, 1:10) and
rat IgG2a for CD105 (BD Biosciences, clone R35–95, 1:10).
Antibodies were conjugated with R-phycoerythrin.
Flow Cytometry
Samples were acquired in polystyrene FACS tubes on a
BD FACS Calibur flow cytometer (BD Bioscience). The instru-
ment was calibrated using CaliBRITE 3 color FACS Comp
beads (BD Bioscience) before acquiring and analyzing each set
of samples using CellQuest Pro software (BD biosciences).
Unlabeled cells were acquired in order to set the forward and
side scatter parameters to center the cell population on the
scatter plot. Fluorescence intensity was adjusted to set the
unlabeled cells within 100–101 on the log scale axis. Cells were
then acquired with an event count set to a total of 1 3 104
events. Data was analyzed using FlowJo software (FlowJo,
LLC). Further details are provided in MIFlowCyt (Supporting
Information).
Population Doubling Time
Freshly prepared CDCs and MSCs (non-cryopreserved),
and cryopreserved CDCs were assessed for growth kinetics
using a population doubling time protocol (PDT) as previ-
ously described (35). Cryopreserved cells were expanded for
3–5 days in tissue culture vessels as described above prior to
the PDT protocol. Briefly, cells were detached from culture
vessels using 0.25% trypsin, pelleted and counted by Trypan
blue dye exclusion. 1 3 104 cells suspended in CEM (CDCs)
or MSCM (MSCs) were plated per well, in six-well plates, in
triplicate for each cell type and each time point. Cells were
detached with trypsin every 3–4 days for two weeks to per-
form cell counts. The doubling time was calculated according
to the formula PDT5 ln(N/N0)/ln2 where N was the final cell
number and N0 was the cell number at the beginning of the
logarithmic increase.
Clonal Growth Assay
CDCs were trypsinized from culture vessels, counted and
plated at very low density (20 cells/cm2) on fibronectin coated
25 cm2 flasks. After 24 h individual cells were visualized on an
Olympus inverted microscope (model CKX415F; Olympus
Corporation). The culture vessel was observed daily for 10
days to identify the formation of colonies. Cells were dis-
counted from analysis if more than one cell was present in the
field of view of a low power objective lens (4 x magnification
objective) at the start of the culture period. Images were cap-
tured with a color digital camera (GT Vision Ltd.). Colony
size was measured using ImageJ software version 1.50i
(National Institute of Health).
Sphere Size Assessment
To assess the diameter of spheres formed from fresh
CDCs and cryopreserved CDCs, cells were seeded at a density
of 1 3 105/cm2 on an ULA surface. The spheres formed were
tracked with culture time and sphere number and diameter
measured at 5 days using ImageJ software. These parameters
were compared to primary spheres that were formed by fresh
CDCs at the same time point as detailed above in the prepara-
tion of cardiosphere-derived cells section.
Differentiation Capacity of CDCs and MSCs
MSCs were induced to differentiate toward osteogenic,
adipogenic (26–28), or smooth muscle (14) lineages as previ-
ously reported.
Osteogenic differentiation. MSCs were plated in six-well
plates (5,000 cell/cm2) and cultured to 80% confluence before
induction. Osteogenic induction medium consisted of
DMEM with 10% FBS supplemented with dexamethasone
(100 nM), ascorbic acid (0.2 mM) and b-glycerophosphate
(10 mM) (all from Sigma-Aldrich) with P/S. Medium was
changed every 2–3 days. After 14 days of induction, extracellu-
lar calcium deposits were assessed using 2% Alizarin Red S
(Sigma-Aldrich) staining at pH 4.3.
Adipogenic differentiation. MSCs were plated in six-well
plates (8,000 cell/cm2) and cultured to 90–100% confluence
before induction. Induction wells were subjected to alternat-
ing cycles of inductive medium (72 h) followed by mainte-
nance medium (24 h) repeated six times. Inductive medium
consisted of DMEM with 10% FBS supplemented with dexa-
methasone (1 mM), 1% insulin, indomethacin (100 mM), 3-
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isobutyl-1-methylxanthine (100 mM) (all Sigma-Aldrich) with
P/S. Oil-Red-O staining was used to assess intracytoplasmic
lipid accumulation.
Smooth muscle and endothelial differentiation. Fresh
CDCs, MSCs, and cryopreserved CDCs were seeded onto
fibronectin-coated Nunc Lab-Tek chamber slides (Thermo
Fisher Scientific), allowed to reach 80% confluence and sub-
jected to differentiation media for 12–13 days. Smooth muscle
differentiation media consisted of IMDM with 1% L-gluta-
mine, 1% P/S and 10 ng/ml platelet-derived growth factor-b
(PDGF-b, Preprotech; 100-14B). Endothelial differentiation
media consisted of IMDM with 1% L-glutamine, 1% P/S and
50 ng/ml vascular endothelial growth factor (VEGF, Prepro-
tech; 100–20 A). Immunocytochemistry was performed to
assess formation of actin fibers or expression of von Wille-
brand factor (vWF).
Cardiomyocyte differentiation. Following monolayer cul-
ture, fresh CDCs and cryopreserved CDCs were dissociated
and seeded at a density of 1 3 105/cm2 on either 24 or 6 well
plates on a cell-repellent surface (Greiner Bio One) to form
secondary cardiospheres. Once spheres had formed (3–5
days), media in inductive wells was changed to Cardiomyocyte
Differentiation Kit media according to the manufacturers
instructions (Thermo Fisher Scientific) and continued for 12–
14 days. Next, spheres were harvested and attached to FBS-
coated chamber slides for 18 h. Expression of cardiac troponin
T (cTNT) was assessed by immunocytochemistry. Expression
of cTNT was also assessed on individual cells as described for
smooth muscle and endothelial differentiation.
Immunocytochemistry
Following termination of differentiation, cells were fixed in
4% PFA for 10 min then blocked and permeabilized in protein
block solution (DAKO) containing 1% saponin (Sigma-
Aldrich) for 1.5 h. Cells were incubated at 48C with a primary
antibody for 1 h then secondary antibodies for 1 h. The primary
antibodies used were: monoclonal mouse anti-cardiac troponin
T (Abcam, clone 1C11; 1:500 dilution), mouse anti-smooth
muscle actin (Sigma-Aldrich, clone 1A4; 1:200) and polyclonal
rabbit anti-von Willebrands factor (Abcam, 1:400). Fluorescein
isothiocyanate (FITC) labelled secondary antibodies were pur-
chased from Abcam (polyclonal goat anti-mouse IgG, 1:500)
and Biolegend (polyclonal donkey anti-rabbit IgG, 1:250). Con-
trol slides consisted of unstained cells, undifferentiated cells and
secondary antibody only stained slides. Slides were mounted
with Vectashield containing 40, 6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories Ltd). Cells were visualized with an
Olympus BX60 microscope (Olympus Corporation) equipped
with a CoolLED pE-2 fluorescence illumination system
(CoolLED Ltd.) and images captured using a QImaging
QICAM digital camera.
Figure 1. Representative photomicrographs showing the formation of cardiosphere-derived cells (CDCs) and mesenchymal stem cells
(MSCs). Panel (A) stromal-like outgrowth cells from an atrial tissue explant with phase-bright cells (long arrows) migrating over the spin-
dle like cell monolayer. The phase-bright cells were harvested and further grown in suspension culture to form cardiospheres (B). Hetero-
geneous sized cardiospheres were typically formed. Cardiospheres were collected by aspiration and seeded on fibronectin-coated tissue
culture plastic to form cardiosphere-derived cells (CDCs) which are the fibronectin adherent population emerging from the cardiosphere
(C) and shown at higher magnification (D). CDCs that were cultured following cryopreservation (E) had a similar morphology to fresh
CDCs (D). The CDC population typically contained a mixture of spindle like cells (white arrows) among more rounded cells (black arrows).
These are representative results for atrial tissue from five dogs. MSCs showed typical spindle like cell morphology (F). Scale bars5250
mm.AQ10
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Statistical Analysis
GraphPad Prism 7 software (GraphPad Software Inc. CA,
USA) was used for statistical analysis. Data was assessed for
normality. All data is presented as the mean6 SEM unless
stated otherwise. Comparisons between two independent
samples were performed using student’s two-tailed t test and
between three or more groups using one-way ANOVA with
post hoc Tukey analysis. A P values of< 0.05 was considered
significant.
RESULTS
Cardiosphere Formation
CDCs were isolated and expanded from dogs (n5 5) of
different breeds or of non-pedigree origin. Donor characteris-
tics are summarized in Supporting Information Table S1.
Within 5–7 days a stromal-like monolayer of cells emerged
from the explants above which phase-bright cells migrated
(Fig.F1 1A). The phase-bright cells formed spheres (Fig. 1B).
Early passage CDCs showed a heterogeneous population of
cell morphologies consisting of both long spindle shaped cells
and rounded cells (Fig. 1C,D). CDCs had a post-
cryopreservation viability of 95–98% after being frozen for 3
months and could be further expanded in monolayer culture
on fibronectin-coated flasks. Culture expanded cells showed a
similar heterogeneous morphology (Fig. 1E). By comparison
MSCs prepared from adipose tissue showed typical spindle
shaped cells, which were homogeneous in morphology (Fig.
1F).
Cardiosphere Characteristics
Both cryopreserved and non-cryopreserved CDCs were
able to readily form into secondary cardiospheres when plated
onto a low attachment surface. The diameter of primary, sec-
ondary and cryopreserved cardiospheres was compared. Sec-
ondary spheres formed by fresh CDCs were 20% smaller than
primary spheres (Fig. F22A; P< 0.0001). Strikingly, the spheres
formed by cryopreserved cells were approximately three times
larger than those formed from fresh CDCs (Fig. 2A;
P< 0.0001).
Population Doubling and Cloning Potential
The cloning potential and growth kinetics were assessed
for CDCs prior to and after cryopreservation. The population
doubling time was similar between the two groups (Fig. 2B;
Figure 2. Comparison of growth characteristics of canine cardiosphere-derived cells (CDCs). (A) Sphere diameters of primary and second-
ary cardiospheres obtained from fresh cells and from cryopreserved cells. Secondary spheres were significantly smaller than primary
spheres and spheres obtained from cryopreserved CDC were significantly larger than either primary or secondary spheres. (B) There was
no significant difference in the PDT between fresh and cryopreserved cells but both were significantly slower compared to canine adipose
MSCs. (C) Colony diameter for fresh and cryopreserved CDCs plated at low density. Colony size measurements shown were taken at days
4 and 7 and showed no significant difference between the two cell populations on either day. (D) Clonal expansion of CDCs from both
fresh and cryopreserved cells. Scale bars5 250 mm.
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fresh vs. cryopreserved; 57.136 5.27 h vs. 48.946 9.55 h,
P5 0.71). As a comparison, canine MSCs had a significantly
faster population doubling time compared to both fresh and
cryopreserved CDC (Fig. 2B; 30.46 h, P< 0.05). There was no
significant difference in the diameter of clonal colonies
between the two groups by Day 7 (Fig. 2C; fresh versus cryo-
preserved; 1.306 0.19 mm versus 1.206 0.13 mm, P5 0.73).
Both cell populations were able to form clonal colonies from
single cells when plated at very low density (Fig. 2D).
Multipotency of CDCs and MSCs
When fresh and cryopreserved CDCs were placed into
suspension culture to form secondary cardiospheres, they
expressed high levels of troponin T within their cytoplasm fol-
lowing induction with a cardiomyocyte medium (Fig.F3 3A–I).
In addition, single plated CDCs showed cytoplasmic troponin
T staining that was mostly disorganized (Fig. 3J), but a small
number of cells demonstrated early fiber alignment and stria-
tion (Fig. 3K). Both fresh and cryopreserved CDCs also dem-
onstrated capacity for differentiation toward lineages of
endothelium (positive expression of vWF) and smooth muscle
(positive expression of a-smooth muscle actin, Fig. 3L–Q).
MSCs also differentiated into a smooth muscle phenotype
when induced with PDGF-b and expressed smooth muscle
actin (Fig. 3R,S) and showed positive staining for Alizarin Red
S and Oil Red O following induction in osteogenic or adipo-
genic medium, respectively, when compared to control cells
(Fig. F44A–D).
Surface Marker Expression Profile
Flow cytometry analysis showed fresh CDCs consisted of a
high proportion of CD1051 (89.0%6 4.98) and CD441
(99.68%6 0.13) cells, low proportions of CD901 (23.36%
6 9.78), CD1171 (13.17%6 8.67), CD291 (2.92%6 2.46) cells,
and a negligible proportion of CD451 cells (0.005%6 0.003,
Fig. F55A–F). In contrast MSCs showed a high proportion of
CD901 (99.60%6 0.30), CD441 (99.85%6 0.05), and CD1051
(76.55%6 22.35) cells and a small fraction of CD341 cells
(1.80%6 1.76). CD1171 (0.92%6 0.34), CD451 (0.015%
6 0.005), and CD291 (0.57%6 0.46) cells represented a very
Figure 3. Cardiac, smooth muscle, and endothelial differentiation. Fresh and cryopreserved canine cardiosphere-derived cells (CDCs)
demonstrated expression of cardiac troponin T (cTNT, green fluorescence) following repeat sphere formation in the presence of cardio-
myocyte differentiation medium (A–I). Individual CDCs for the majority showed disorganized cTNT protein (J), although a small number
of cells showed an early-striated fiber pattern (K). CDCs were also able to differentiate toward a smooth muscle lineage as shown by
expression of alpha-smooth muscle actin (a-SMA, green fluorescence) when compared to control cells (L and M), this ability was unaf-
fected by cryopreservation (N). Expression of von Willebrand factor (vWF, green fluorescence) demonstrating a commitment to the endo-
thelial lineage in fresh and cryopreserved cells (O–Q). MSCs showed marked up-regulation of a-SMA on induction when compared to
control cells (P and Q). Nuclei are counterstained with DAPI (blue fluorescence). Scale bars5 50 mm (D–I and K) 25 mm (other panels).
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small fraction (Fig. 5M–R). Interestingly, the percentage of
CD341 cells was variable with passage number with low percen-
tages in low passage CDCs (P1–2; 7.18%6 4.03) but increased
to moderate and high percentages with further passaging (P4–6;
59.75%6 3.45, P5 0.003, Fig. F66A–C), with high percentages fol-
lowing cryopreservation (79.35%6 4.85, Fig. 6D). This was in
contrast to the proportion of CD901 cells, which was higher in
unpassaged cells (P0; 42.55%6 13.65) but decreased in P4–5
Figure 4. Adipogenic and osteogenic differentiation of mesenchymal stem cells (MSCs). Photomicrographs depicting Alizarin Red S stain-
ing for osteogenic differentiation: (A) control (non-induced) cells and (B) induced cells showing positive red staining for mineral deposi-
tion. Oil Red O staining for adipogenic differentiation: (C) control (non-induced) cells, (D) induced cells showing intracellular deposits of
red stained oil droplets. Images are representative of differentiation of cells derived from five dogs. Scale bar5250 mm.
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Figure 5. Flow cytometry contour plots for surface marker expression analysis of cardiosphere-derived cells (CDCs) and mesenchymal
stem cells (MSCs). CDCs show intermediate proportions of CD901 cells (A), negligible CD451 cells (B), high proportion of CD441 cell (C),
low numbers of CD1171 cells (D), intermediate to high CD341 cell percentage (E) and high CD1051 cell portion (F). MSCs showed a high
percentage of CD901 cells (G), low proportion of CD451 cells (H), high CD441 proportion (I), negligible CD1171 (J) and CD341 proportion
(K), and a high CD1051 proportion (L). Blue contours denote isotype control and red contours denote antibody labeled samples. Anti-
bodies were R-PE conjugated.
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(15.04%6 9.77, P5 0.03, Fig. 6E–G). The CD901 fraction was
low in CDCs following cryopreservation (3.03%6 1.41, Fig.
6H). Other markers (CD105, CD44, CD45, CD117, and CD29)
exhibited a similar expression profile between fresh and cryopre-
served CDCs.
DISCUSSION
In this study, we derived CDCs from multiple donor ani-
mals for characterization prior to and following cryopreserva-
tion, since to the authors knowledge the effect of freezing on
CDCs has not been assessed in any species. Understanding the
effect of cryopreservation on these cells is vital for conducting
clinical trials using frozen CDCs. The effect of cryopreserva-
tion is well characterized for MSCs (37,38); however, previous
attempts in our laboratory to freeze canine cardiac stem cells
suggested they may be more labile than MSCs to cryopreser-
vation. We utilized atrial tissue as previous reports indicated a
higher number of c-Kit1 cells present within the atria and
therefore potentially a greater number of cardiac stem cells
may be obtained compared to the ventricle (17,24). Atrial tis-
sue has also been used previously to isolate canine cardiac
stem cells (33). We demonstrate for the first time that cryo-
preservation of canine CDCs does not affect their vital stem
cell characteristics. First, there were no significant differences
in clonal growth and population doubling characteristics sug-
gesting that CDCs tolerate freezing. The ability of CDCs to
differentiate was also unaffected since they were able to
express a-smooth muscle actin, von Willebrand factor and
troponin T indicating commitment to the smooth muscle,
endothelial and cardiomyocyte lineages, respectively, as
reported by others for fresh cells (25,31). Furthermore, fresh
and cryopreserved CDCs demonstrated cardiomyogenic
potential following secondary sphere formation and culture in
the presence of cardiomyocyte differentiation media. Cytolog-
ical staining on individual cells shows mostly an immature
troponin organization, although a small fraction of cells dem-
onstrated a more complex organization, characterized by the
emergence of a striated pattern.
Conversely, the process of cryopreservation did alter the
proportions of certain cell surface markers. Specifically, the
CD341 fraction was increased after culture of cryopreserved
CDCs. CD34, a transmembrane phosphoglycoprotein, is
found on a diverse range of cells and appears to have multiple
functions. It has been associated with cell-cell adhesion and
highly proliferative cells (39–41). CD34 is often used as an
exclusion criteria for MSCs (42), however a more recent litera-
ture review indicates its presence on some MSC populations
(specifically adipose derived MSCs) and is expressed by a
diverse range of other progenitor cells (43). The higher prolif-
erative capacity of the CD341 population (34–36) may
explain the increase we observed with passage number and
following cryopreservation. CD341 cells also appear highly
tolerant to freezing when compared to other nucleated cell
types and therefore may have better survival in the heteroge-
neous CDC population (44). This may have clinical relevance
as experiments in animal models of myocardial infarction
using CD341 purified cell populations showed an increased
cellular persistence within the myocardium and showed posi-
tive effects on heart function (45,46).
In comparison with other species, early passage (P2)
human CDCs exhibit a similar CD341 population (approxi-
mately 10%) (47). However, another study reported fewer
Figure 6. Flow cytometry comparing CD34 and CD90 expression on cardiosphere-derived cells (CDCs) at different passages and post-
cryopreservation. CD341 cell were negligible in P0 cells (A; 1.1%) but increased from P1 to P4 (B and C, 14.8% and 55.3%). Cryopreserved
cells showed a high CD341 proportion (D, 84.2%). Conversely the CD901 portion was reduced with passage number. P0 CDCs showed a
high CD901 percentage (E, 56.2%) and 50.7% at P1 (F), and 28.9% at P4 (G). CD90 was absent in cryopreserved CDCs (H). Blue contours
denote isotype control and red contours denote antibody labeled samples.
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CD341 cells (1%) in human CDCs of undefined passage
number (48). It has also been noted that increasing media
serum content from 10% to 20% increases the CD341 popu-
lation from 0.9% to 7.5% (31). Cardiac progenitor cells grown
directly from rat heart explants (without the cardiosphere
step) declined in their CD341 population over a culture
period of 35 days (23).
Furthermore, there were varying proportions of CD901
cells, which was both inter-donor (the variability between
donors) and intra-donor dependent (the variability within a
donor, dependent on culture conditions). The CD901 fraction
also decreased following cryopreservation and increasing pas-
sage number of fresh cells. CD90 (Thymocyte antigen-1; Thy-
1) is a commonly used marker for MSCs in all reported spe-
cies, including canines (35,49–51). The CD901 population in
our CDC preparations exists as a small fraction, as noted by
others (20,29,45). Our finding that the CD90 population can
be manipulated by passaging or cryopreservation may have
clinical implications as this population appeared to reduce the
therapeutic efficacy of CDCs in a rodent model of myocardial
infarction (24).
Cryopreserved CDCs formed cardiospheres that were
approximately three times larger than their fresh counterparts.
This may be due to the higher CD341 fraction increasing the
cell-cell adhesion efficiency. Alternatively this may be an integ-
rin dependent interaction as this has previously been shown
to significantly increase the adherence and cell-cell binding in
MSCs (52). This may be clinically relevant as the larger size
could predispose them to arteriole blockage and subsequent
tissue ischemia. Sphere size would therefore need to be con-
trolled by the use of aggregation wells (53).
In comparison with other species, canine CDCs exhibit
remarkable phenotypic similarities to mouse, rat, human, and
porcine cells (21,22,28,54,55). As we elucidated in the intro-
duction, canines are a unique naturally occurring model for
non-ischemic cardiomyopathy in humans, specifically ARVC
(8–10).AQ3 The effect of cryopreservation on human CDCs is
poorly understood; therefore given the similarities with canine
cells the present study also provides vital translational infor-
mation to the human field. Also phenotypically the sphere
size formed from fresh cells is similar to reports in other spe-
cies (21,31), conversely the large spheres from cryopreserved
cells has not been noted previously. There are other notable
differences. Firstly, differentiation of canine CDCs to func-
tioning cardiomyocytes appears challenging. Methods
attempting to translate mouse and rat differentiation proto-
cols to canine cells have proved only partially successful
(25,33). We also found similar difficulties in using cardiac dif-
ferentiation media designed for mouse and human iPSCs.
Additionally the c-Kit1 proportion in our atrial derived CDCs
was higher than that reported in mouse, human and canine
ventricular derived CDCs (22,23,25,30,31). C-Kit1 cells have
been reported to be localized in areas within the heart with
low hemodynamic stress, such as the atria in humans
(17,18,56). The location of c-Kit expressing cells in the canine
heart has not been described but the tissue compartment
(atria) source likely explains the greater c-Kit1 population in
our CDCs. Previous studies with canine CDCs have examined
ventricular tissue from a single donor (25,30) which limits the
comparative interpretation with our study.
In conclusion, we conduct for the first time phenotypic
analysis of CDCs prior to and following cryopreservation.
Our most important finding is that the key stem characteris-
tics of these cells are unchanged by this process. Changes were
noted in the populations of cells expressing CD34 and CD90;
however, the clinical significance of this is unknown, but
based on previous literature could be beneficial. Our results
show promise for the creation of cryopreserved cell banks for
usage in future clinical trials.
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